Loading…
← CockpitCompetitor Analysis › MDXG MiMedx Group, Inc.Open in the cockpit ↗

MiMedx Group, Inc.MDXGCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum weak 21
Mkt cap
$464M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$5.99M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-32.9 pp
WACC 10.9%
Hurdle
-0 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$3.18
1D0.0%
1W-4.2%
1M-24.8%
3M-26.1%
6M-16.1%
YTD-53.0%
1Y-55.2%
ATR %5.9%
Beta0.60
52w lowhigh57.3% off high

What MiMedx does

Employees: 808

MiMedx at a glance

Size MiMedx (MDXG) is a United States Health Care company (Medical Specialties) with a market value of $464M, the 2732nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.18 on 18 Nov 2026.

Performance Over six months the shares fell 16.1%, against -14.2% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 22.8% over the last twelve months (peer median +3.9%); the operating margin is -8.3% (peer median 6.1%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 3.6× (cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 32.9 points below its cost of capital (10.9% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026MDXG 88Peer median 87
Six months, rebased to 100: MiMedx against the median of its 20 peers (local-currency closes).

MiMedx financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$304M$419M$349M$321M$268M
Revenue growth—+20%+9%+20%—
Gross profit$234M$344M$287M$265M$217M
EBITDA-$17.3M$78.8M$62.4M$40.5M-$10.7M
Net income-$19.2M$48.6M$42.4M$58.2M-$30.2M
Free cash flow$19.0M$73.0M$64.5M$24.8M-$19.4M
Capital expenditure$3.81M$3.12M$1.72M$2.15M$2.68M
Total debt$0$22.5M$24.8M$50.5M$52.5M

Quarterly statements and history in the cockpit →

MiMedx competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%4549300289468530603309002016ANGOCEVI300246301033002932CU6300110603520688026MEDXMOBISI688580MDXG6-month return →1-month return →
Up and to the right = strong over both horizons. MiMedx is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×200×400×4549300289468530603309002016301033MOBISIMDXGRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MiMedx is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%300289603309002016603987CEVI300246301033688606300110688026MEDX688580MDXGGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MiMedx is the large dot.

MiMedx competitors and peer comparison

How MiMedx compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MiMedx against its 20 peers (data as of 18 Nov 2026)
MeasureMDXGPeer medianRank in peer set
1-month return-24.8%-3.4%lowest of 21
6-month return-16.1%-14.2%10th lowest of 21
Distance from 52-week high-57.3%-36.1%lowest of 21
Revenue growth (TTM)-22.8%+3.9%3rd lowest of 20
Operating margin-8.3%6.1%5th lowest of 20
EV / Sales1.1×3.6×cheapest of 19
Growth the price implies (Req g, 7 yrs)10.9%6.5%6th most demanding of 13
Growth delivered (Del g)+11.0%+1.2%2nd highest of 13
Hurdle (Req g minus delivered)-0.1 pp+3.7 pp6th least demanding of 13
ROIC minus cost of capital-32.9 pp-1.6 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MiMedx MDXGUnited States$464M-16%-23%-8%1.1×10.9%+11.0%
Eiken Chemical 4549.TJapan$466M-20%+4%6%1.6×n/an/a
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%8.2×36.0%-6.9%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%410.3×n/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%3.8×21.5%-11.7%
AngioDynamics ANGOUnited States$476M-4%+8%-6%1.4×n/an/a
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%1.5×-1.0%-2.8%
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%3.3×5.8%+0.3%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%4.8×20.6%+2.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Mobia Medical MOBIUnited States$434M+2%+105%-145%8.8×n/an/a
Shoulder Innovations SIUnited States$432M+39%+55%-54%5.5×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%

Questions

Which companies are MiMedx's closest peers?
The cockpit's peer set: Eiken Chemical (4549.T), Beijing Leadman Biochemistry (300289.SZ), PROTEINA (468530.KS), WELL LEAD MEDICAL (603309.SS), Guangdong Shirongzhaoye (002016.SZ), AngioDynamics (ANGO), Shanghai Kindly Enterprises Development (603987.SS), CellaVision (CEVI.ST).
Is MiMedx expensive compared with its peers?
On ev / sales it trades at 1.1× against a peer median of 3.6×, cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has MiMedx stock performed?
Over six months to 18 Nov 2026 the shares returned -16.1% against -14.2% for the median peer; over one year -55.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.